

DAFTAR PUSTAKA

1. Nurhayati, Zaenal Arifin H. Analisis Faktor-Faktor Yang Berhubungan Dengan Kejadian Kanker Payudara. *Holistik J Kesehat.* 2019;13(2):175–85.
2. Simon A, Robb K. Breast Cancer. *Cambridge Handb Psychol Heal Med Second Ed.* 2021 Aug 7;577–80.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.* *Ca Cancer J Clin.* 2021; 71: 209-49.
4. Kemenkes RI. Infodatin. Beban Kanker di Indonesia. Kementerian Kesehatan Republik Indonesia. 2019: 1-16
5. Marpaung MRA, Khambri D, Asterina. Karakteristik Penderita Kanker Payudara dengan Metastasis Jauh Tunggal di Kota Padang Tahun 2014-2018. *Jikesi.* 2020; 2(1): 82- 9.
6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.* *CA Cancer J Clin.* 2018; 68: 394-424.
7. Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, et al. *Impact of Molecular Subtypes on Metastatic Behavior and Overall Survival in Patients with Metastatic Breast Cancer: A Single- Center Study Combined with a Large Cohort Study Based on The Surveillance, Epidemiology and End Results Database.* 2020; 20(4): 1-11.
8. Firdaus VRP, Asri A, Khambri D, Harahap WA. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *JKA.* 2016; 5(1): 165-72.
9. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Srici F, et al. *Association between common risk factors and molecular subtypes in breast cancer patients.* *The Breast.* 2013; 22: 344-50
10. Soediro R, Nugroho RS, Gondhowiardjo SA, Djoerdan Z, Poetiray EDC. Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2. *Journal of the Indonesian Radiation Oncology Society.* 2010; 1(2): 43-7
11. Mohammed AA. *Prognostic parameter differences in breast cancer patients between luminal A and luminal B types after application of the new classification according to Ki67 score.* *Int J Surg Open.* 2021; 34: 1-8

12. Harris L, Fritsche H, Mennel R et al. *American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol* 2007; 25: 5287–5312.
13. Guadagni F, Ferroni P, Carlini S et al. *A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res* 2001; 7: 2357–2362.
14. Tondini C, Hayes DF, Gelman R et al. *Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res* 1988; 48: 4107–4112.
15. Lauro S, Trasatti L, Bordin F et al. *Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res* 1999; 19: 3511–3515.
16. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM. *c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat.* 1998 Sep;51(2):109-19. doi: 10.1023/a:1005734429304. PMID: 9879773.
17. Zhai K, Wang W, Wang Y, Liu JY, Zhou Q, Shi HZ. *Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study. J Thorac Dis* 2014;9(12):5220-5229. doi: 10.21037/jtd.2017.11.62
18. S. Park, H. K. Ahn, T. Lim, Y. H. Park, J. S. Ahn, and Y. Im. *CA 15-3 elevations according to breast cancer subtypes at initial diagnosis of metastatic breast cancer (MBC). Journal of Clinical Oncology* 2011 29:15_suppl, e11109-e11109
19. Geng B, Liang MM, Ye XB, and Zhao WY. *Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology.* 2014;3(1): 232–6.
20. Colomer R, Ruibal A, Genollá J, Rubio D, Del Campo JM, Bodi R, Salvador L. *Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat.* 1989 Mar;13(2):123-33. doi: 10.1007/BF01806524. PMID: 2730960.
21. Banerjee AK, Willetts I, Robertson JF, Blamey RW. *Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol.* 1994 Feb;20(1):33-6. PMID: 8131866.
22. Crnjac A, Sok M, Kamenik M. *Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J*

Cardiothorac Surg. 2004 Aug;26(2):432-6. doi: 10.1016/j.ejcts.2004.03.010. PMID: 15296910.

23. Skok K, Hladnik G, Grm A, Crnjac A. *Malignant Pleural Effusion and Its Current Management: A Review. Medicina (Kaunas).* 2019 Aug 15;55(8):490. doi: 10.3390/medicina55080490. PMID: 31443309; PMCID: PMC6723530.
24. Gasparri R, Leo F, Veronesi G, De Pas T, Colleoni M, Maisonneuve P, Pelosi G, Galimberti V, Spaggiari L. *Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer.* 2006 Jan 15;106(2):271-6. doi: 10.1002/cncr.21623. Erratum in: *Cancer.* 2006 Sep 15;107(6):1421. DePas, Tommaso [corrected to De Pas, Tommaso]. PMID: 16342163.
25. International Agency for Research on Cancer (2018). *GLOBOCAN 2018: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2018. The Global Cancer Observatory.* <http://gco.iarc.fr/today/>
26. *Globocan 2020. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*
27. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.* 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: *CA Cancer J Clin.* 2020 Jul;70(4):313. PMID: 30207593
28. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; *ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.* 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298. PMID: 26314782.
29. Kementerian Kesehatan Republik Indonesia. *Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline).* *J Kesehat Masy.* 2019;4(4):1-50. <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
30. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. *Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin.* 2021; 71: 209-49
31. Perhimpunan Ahli Bedah Onkologi Indonesia. *Panduan Penatalaksanaan Kanker 2020. II.* (Djoko H, Haryono S, Arief HW, eds.). PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia); 2020.

32. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Srici F, et al. *Association between common risk factors and molecular subtypes in breast cancer patients. The Breast.* 2013; 22: 344-50
33. Szymiczek A, Lone A, Akbari MR. *Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin Genet.* 2021;99(5):613–37.
34. Jennifer J. Gao, Sandra M. Swain, *Luminal A Breast Cancer and Molecular Assays: A Review, The Oncologist, Volume 23, Issue 5, May 2018, Pages 556– 565, <https://doi.org/10.1634/theoncologist.2017-0535>*
35. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. *Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA* 2006; 295: 2492-2502 [PMID: 16757721 DOI: 10.1001/ jama.295.21.2492
36. Creighton CJ. The molecular profile of luminal B breast cancer. *Biologics* 2012; 6: 289-297 [PMID: 22956860 DOI: 10.2147/BTT.S29923]
37. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. *Gene expression pro- filing identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics* 2009; 2: 37
38. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. *Mo- lecular classification of estrogen receptor-positive/lumi- nal breast cancers. Adv Anat Pathol* 2012; 19: 39-53
39. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. *Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med* 2010; 1: 747-754
40. Ignatiadis M, Bedard P, HaibeKains B, Singhal S, Loi S, Criscitiello C, Desmedt C, Bontempi G, Piccart M, Piccart M, SotiriouC. *A meta analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal like breast cancer. Cancer Res* 2009; 69: 106
41. Fu X, Osborne CK, Schiff R. *Biology and therapeutic poten- tial of PI3K signaling in ER+/HER2-negative breast cancer. Breast* 2013; 22 Suppl 2: S12-S18
42. Gutierrez C, Schiff R. *HER2: biology, detection, and clinical implications. Arch Pathol Lab Med* 2011; 135: 55-62
43. De Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S. *Concordance of clini- cal*

and molecular breast cancer subtyping in the context of preoperative chemotherapy response. *Breast Cancer Res Treat* 2010; 119: 119-126 [PMID: 19669409 DOI: 10.1007/s10549-009-0499-6]

44. Prat A, Perou CM. *Deconstructing the molecular portraits of breast cancer. Mol Oncol* 2011; 5: 5-23
45. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B. *Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol* 2006; 24: 5658-5663
46. Yin L, Duan JJ, Bian XW, Yu SC. *Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res.* 2020;22(1):1-13.
47. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. *Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res* 2009; 15: 2302-10.
48. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A. *Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer* 2009; 45: 2792-8
49. Fakhriyyatur Rahmi M, Rikarni, Nora Harminarti. Hubungan Kadar Cancer Antigen 15-3 Serum dengan Metastasis Kanker Payudara. 2020. *Jurnal Ilmu Kesehatan Indonesia.* 1(3). 371-8.
50. Duffy MJ. *Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clinical Chemistry.* 47 (4): 624-30. 2001.
51. Geng B, Liang MM, Ye XB, Zhao WY. 2014. *Association of CA15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology.*
52. Hosseini S, Razmjoo S, Aryandi S, Barat T. 2015. *CEA and CA15-3 serum level in metastatic breast cancer and it's correlation with distant metastasis. Biomedical & Pharmacology Journal.*
53. Yerushalmi, R. 2012. *Tumor marker in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Annals of Oncology.*
54. Mayse M.L. *Non malignant pleural effusions. In: Fishman A.P, editor. Fishman's pulmonary diseases and disorders. 4th ed. New York: Mc Graw Hill, 2008; p. 1487-504.*

55. Maskell NA, Butland RJA. *BTS guidelines for the investigation of unilateral pleural effusion in adults. Thorax.* 2003;58:8-17.
56. Marel M. *Epidemiology of pleural effusion. Eur Respir Mon.* 2002;22:146-56
57. Mangunegoro H. *Masalah efusi pleura di Indonesia. J Respir Indo.* 1998;18:48-50.
58. Detterbeck FC, Jones DR, Morris DE. *Palliative treatment of lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, eds. Diagnosis and Treatment of Lung Cancer. WB Saunders Company, Philadelphia, 2001; pp. 428-33.*
59. Scagliotti GV. *Symptoms, signs and staging of lung cancer. In: Spiro SG, ed. Lung Cancer. ERS Monograph, 2001; p. 92.*
60. Lee YTN. *Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol* 1983; 23: 175-180.
61. Banarjee AK, Willets I, Robertson JF, Blamey RW. *Pleural effusion in breast cancer: a re-view of the Nottingham experience. Europ J Surg Oncol* 1994: 20: 33-6
62. Bakir K. *Malign pleural effüzyonların tanısında sitopatoloji. TTD Plevra Bülteni.* 2009; 3: 9-12.
63. Bielsa S, Martín-Juan J, M. Porcel J, Rodriguez- Panadero F. *Diagnostic and Prognostic Implications of Pleural Adhesions in Malignant Effusions. J Thorac Oncol* 2008; 3: 1251-6. [SEP]
64. Heffner J.E. *Diagnosis and management of malignant pleural effusions. Respirology* 2008; 13: 5-20
65. American Thoracic Society. *Management of malignant pleural effusions. Am J Respir Crit Care Med* 2000; 162: 1987-2001.
66. Light RW. *Clinical practice. Pleural effusion. N Engl J Med* 2002; 346: 1971-7.
67. Shuey K, Payne Y. *Malignant pleural effusion. Clinical Journal of Oncology.* 2005; 9: 529-32
68. Sahn SA. *Pleural diseases related to metastatic malignancies. Eur Respir J* 1997; 10: 1907-13.
69. Grodzin CJ, Balk RA. *Indwelling small pleural catheter needle thoracentesis in the management of large pleural effusions. Chest* 1997; 111: 981-8.

70. Chung CL, Chen YC, Chang SC. *Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion*. *Chest* 2003; 123; 1188-95.
71. Rittgers RA, Loewenstein MS, Fienerman AE, Kupchik HZ, Warcel BR, Koff RS, Zamcheck N. *Carcinoembryonic antigen levels in benign and malignant pleural effusions*. *Ann Int Med* 1978; 88: 631-4.
72. Kandylis K, Vassilomanolakis M, Baziotis N, Papadimitriou A, Tsoussis S, Ferderigon A, Efremidis AP. *Diagnostic significance of the tumor markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer*. *Ann Oncology* 1990; 1: 435-8.
73. Nam, H. S. (2014). *Malignant pleural effusion: Medical approaches for diagnosis and management*. *Tuberculosis and Respiratory Diseases*, 76(5), 211–217
74. Antony VB, Loddenkemper R, Astoul P, et al. *ERS/ATS Statement: Management of Malignant Pleural Effusions*. *Eur Respir J* 2001; 18: 402-19.
75. Sahn SA. *Malignancy metastatic to the pleura*. *Clin.Chest Med* 1998; 19: 351-61.
76. Sanchez-Armengol A, Rodriguez-Panadero F. *Survival and talc pleurodesis in metastatic pleural carcinoma, revisited*. *Chest* 2003; 104: 1482-5
77. J.Jamnasi, S.Gondhowiardjo, Z.Djoerban, NC.Siregar, EDC Poetiray, AP.Tunggono. *Faktor Risiko Terjadinya Metastasis Jauh Pada Pasien Kanker Payudara*. 2016. *Radioterapi & Onkologi Indonesia* Vol.7(2) Jul 2016: 55-59.
78. Thakur P, Seam RK, Gupta MK, Gupta M, Sharma M, Fotedar V. *Breast cancer risk factor evaluation in a Western Himalayan state: A case-control study and comparison with the Western World*. *South Asian J Cancer*. 2017;6(3):106–109.
79. Amandito, R., Viryawan, C., Santoso, F., Gautami, W., & Soni Panigoro, S. (2013). *The Characteristics of Breast Cancer Patients in "Dharmais" Hospital National Cancer Center Jakarta Based on Occupational and Environmental Status*. *Indonesian Journal of Cancer*, 7(2), 53–59.
80. Gelgel JPP., Christian SI. (2020). *Karakteristik Kanker Payudara Wanita di Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2014-2015*. *Jurnal Medika Udayana*, 9, 52-57.
81. Momenimovahed, Z., & Salehiniya, H. (2019). *Epidemiological characteristics of and risk factors for breast cancer in the world*. *Breast Cancer: Targets and Therapy*, 11, 151–164.

82. Chan D. 2014. *Body mass index and survival in women with breast cancer-systematic literature review and metaanalysis of 82 follow-up studies*. *Ann Onc.* 25(10):1901-1914.
83. Hillers LE, D'Amato J V, Chamberlin T, et al. *Obesityactivated adipose-derived stromal cells promote breast cancer growth and invasion*. *Neoplasia*. 2018;20(11):1161–74.
84. Dilma'aarij, D., Rahardjo, S. S., & Pamungkasari, E. P. (2021). *Meta-Analysis the Effect of Oral and Injection Contraceptives on Breast Cancer*. *Journal of Maternal and Child Health*, 6(2), 238–249.
85. Heikkinen, S., Koskenvuo, M., Malila, N., Sarkeala, T., Pukkala, E., & Pitkaniemi, J. (2016). *Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment*. *Cancer Causes and Control*, 27(2), 249–258.
86. Agustia, D., Rahardjo, S. S., & Poncorini, E. (2022). *Is Contraceptive Injection Cause Breast Cancer? : Meta Analysis*. *MIKIA: Mimbar Ilmiah Kesehatan Ibu Dan Anak (Maternal and Neonatal Health Journal)*, 0825, 64–74.
87. Urban, M., Banks, E., Egger, S., Canfell, K., O'Connell, D., Beral, V., & Sitas, F. (2012). *Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black south african women: Case-control study*. *PLoS Medicine*, 9(3), 1–11.
88. Wijesinghe, K., Jayarajah, U., Gamage, H., De Silva, S., & De Silva, A. (2023). *Breast cancer in lactating mothers: A case series of delayed diagnosis*. *International Journal of Surgery Case Reports*, 102(October 2022), 107856.
89. MA Putri, A., Tejo, J., Probowati, W., & W Siagian, J. (2022). *The Association between The Patient's Age Groups with Stage, Grading, and Molecular Subtype of Breast Cancer*. *Journal of Medicine and Health*, 4(2), 123–130. <https://doi.org/10.28932/jmh.v4i2.4554>
90. Stuebe, A. M., Willett, W. C., Xue, F., & Michels, K. B. (2009). *Lactation and incidence of premenopausal breast cancer: A longitudinal study*. *Archives of Internal Medicine*, 169(15), 1364–1371.
91. Larizadeh, M. H., Nemati, A., Aryaie, M., & Naghibzadeh-Tahami, A. (2023). *The Characteristics of Breast Cancer Patients and Survival Analysis in the Southeast of Iran: A Retrospective Cohort Study*. *Journal of Kermanshah University of Medical Sciences*, 26(4).

92. Li, Z. H., Hu, P. H., Tu, J. H., & Yu, N. S. (2016). *Luminal B breast cancer: Patterns of recurrence and clinical outcome. Oncotarget*, 7(40), 65024–65033.
93. Metzger-Filho, O., Sun, Z., Viale, G., Price, K. N., Crivellari, D., Snyder, R. D., Gelber, R. D., Castiglione-Gertsch, M., Coates, A. S., Goldhirsch, A., & Cardoso, F. (2013). *Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX. Journal of Clinical Oncology*, 31(25), 3083–3090.
94. Shao, Y., Sun, X., He, Y., Liu, C., & Liu, H. (2015). *Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE*, 10(7), 1–11.
95. Li, S., Li, C., Shao, W., Liu, X., Sun, L., & Yu, Z. (2023). *Survival analysis and prognosis of patients with breast cancer with pleural metastasis. Frontiers in Oncology*, 13(May), 1–12.
96. Chen, Y.; Mathy, N.W.; Lu, H. *The role of VEGF in the diagnosis and treatment of Malignant pleural effusion in patients with non-small cell lung cancer (review). Mol. Med. Rep.* 2018, 17, 8019–8030
97. Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010). *Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology*, 28(20), 3271–3277.
98. Kim, J., Lee, Y., Yoo, T., Kim, J., Hyun, J., Park, I., Cho, H., Yang, K., Bae, B., Kim, K., Park, K., & Gwak, G. (2019). *Organ-Specific Recurrence or Metastatic Pattern of Breast Cancer according to Biological Subtypes and Clinical Characteristics. Journal of Breast Disease*, 7(1), 30–37.
99. Cidon, E. U., & Cidon, E. U. (2017). *A brief overview of the role of CA 15.3 in breast cancer. February*, 55–57.
100. Wu, Q., Li, M., Zhang, S., Chen, L., Gu, X., & Xu, F. (2015). *Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis. Experimental and Therapeutic Medicine*, 9(1), 232–238. H
101. Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C. J., Siegal, G. P., & Wei, S. (2015). *Breast cancer subtypes predispose the site of distant metastases. American Journal of Clinical Pathology*, 143(4), 471–478.
102. Wang, Y., Zhou, T., Zhao, S., Li, N., Sun, S., & Li, M. (2023). *A Novel Clinical Prognostic Model for Breast Cancer Patients with Malignant Pleural Effusion: Avoiding Chemotherapy in Low-Risk Groups? Cancer Management and Research*, 15(May), 409–422.

103. Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017). *Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study*. *Oncotarget*, 8(17), 27990–27996.
104. Bai, J., Zhang, X., Kang, X., Jin, L., Wang, P., & Wang, Z. (2019). *Screening of coregenes and pathways in breast cancer development via comprehensive analysis of multigene expression datasets*. *Oncology Letters*, 18(6), 5821–5830. <https://doi.org/10.3892/ol.2019.10979>

